Bone Biologics Corp BBLG
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-11-27 |
| Shares Out. | 1,810,000 |
| Website | bonebiologics.com/ ↗ |
| Phone | 13024977115 |
| Employees | 2 |
| Net Income | -$765,988 |
| Total Assets | $5.0M |
| Total Liabilities | $309,386 |
| Equity | $4.7M |
About Bone Biologics Corp
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Bone Biologics Corp is a publicly traded company under the ticker symbol BBLG on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2023-11-01)